PHARMGen – Patients with Hyperglycemia Assessed for Response to Medications by Genetics

The objective of the study is to examine the impact of diabetes-associated polymorphisms on response to sulfonylurea or metformin monotherapy in a real-world cohort of retrospectively ascertained diabetes patients, using change in HbA1c as the endpoint. Our aim is to enroll 2000 subjects and we are currently enrolling subjects at MGH, BWH, HVMA and NorthShore (Chicago) sites.  We hypothesize that a comparison of the genetic profiles of those who respond well to treatment with the genetic profiles of those for whom the drug was not as effective will help characterize the mode of action of diabetes-associated variants and identify individuals more likely to benefit from specific modes of therapy.  Our second aim is to perform a search for genetic variants that determine the likelihood of response to sulfonylurea or metformin monotherapy in the above cohort.

 

The study is ongoing, we are still enrolling subjects.